Similar articles

• [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].

  Chapple C. Chapple C. Urologe A. 2007 Apr;46(4):422, 424-6; author reply 426, 428. doi: 10.1007/s00120-007-1325-6. Urologe A. 2007. PMID: 17384923 German. No abstract available.
• Cost-effectiveness analysis of solifenacin versus oxybutynin immediate-release in the treatment of patients with overactive bladder in the United Kingdom.

  Hart WM, Abrams P, Munro V, Retsa P, Nazir J. Hart WM, et al. J Med Econ. 2013 Oct;16(10):1246-54. doi: 10.3111/13696998.2013.829079. Epub 2013 Sep 11. J Med Econ. 2013. PMID: 23885660
• Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.

  Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group. Chapple CR, et al. BJU Int. 2004 Feb;93(3):303-10. doi: 10.1111/j.1464-410x.2004.04606.x. BJU Int. 2004. PMID: 14764127 Clinical Trial.
• Solifenacin for overactive bladder: a systematic review and meta-analysis.

  Luo D, Liu L, Han P, Wei Q, Shen H. Luo D, et al. Int Urogynecol J. 2012 Aug;23(8):983-91. doi: 10.1007/s00192-011-1641-7. Epub 2012 Feb 7. Int Urogynecol J. 2012. PMID: 22310924
• Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review.

  Medhi B, Mittal N, Bansal D, Prakash A, Sarangi SC, Nirthi B. Medhi B, et al. Indian J Physiol Pharmacol. 2013 Oct-Dec;57(4):343-53. Indian J Physiol Pharmacol. 2013. PMID: 24968572